PPARα Activation Overcomes Fibroinflammatory Anti-PD-1 Resistance in Liver Cancer via GSDME Pyroptosis
Hepatocellular carcinoma, the most common primary cancer of the liver, has become a major testing ground for immunotherapy. Drugs that block the PD-1 immune checkpoint can restore the ability of T...
Read moreDetails






















